natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the cumulative total amount of histidine, isoleucine, leucine, methionine, phenylalanine, tryptophan, tyrosine, and proline per unit volume in said medium is greater than approximately 25 mM. 
Postupak prema Zahtjevu 1, naznačen time, što je spomenuta kumulativna ukupna količina histidina, izoleucina, leucina, metionina, fenilalanina, prolina, triptofana i tirozina po jedinici volumena u spomenutom mediju veća od približno 25 mM.
monoalkyl ether of diethylene glycol, wherein said formulation comprises fatty alcohols, fatty acids, and fatty esters having a branched or linear acid moiety having 8 or more carbon atoms or having a branched or linear alcohol moiety having 8 or more carbon atoms in a total amount of less than 0.1 % wt. 
- < monoalkil eter dietilen glikola, naznačena time da navedena formulacija sadrži i masne alkohole, masne kiseline, te masne estere koji sadrže razgranate ili ravne kiselinske ostatke s 8 ili više atoma ugljika ili koji sadrže razgranate ili ravne alkoholne ostatke s 8 ili više atoma ugljika u ukupnoj količini koja je manja od 0.1% tež.
Phosphate Salt of the Compound of Formula I 
Datum objave europske prijave patenta:
In one embodiment, wherein the curing time is measured according to method 1, the curing temperature is defined to be the target inlet air temperature and the starting point of the curing step is defined to be the point in time when the inlet air temperature reaches the curing temperature. 
Postupak prema zahtjevu 13, naznačen time da temperaturni profil tijekom koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura poželjno barem oko 68 "€ i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 30 minuta do oko 20 sati.
The method according to claim 19 wherein the method of contacting is by administration of the compound from a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što se primijenjuje kroz dozator za lijek koji se bira iz skupine koju čine inhalator sa spremnikom za suhi prah, višedozni inhalator sa suhim prahom i inhalator za odmjerene doze.
a contiguous sequence of the human λ light chain locus that spans from hVλ3-27 through hVλ3-1; or 
graničnu sekvencu lokusa humanog lakog lanca λ koja se proteže od hVλ3- 27 do hVλ3-1; ili
measuring the concentration of IGFBP2 in a sample that has been obtained from said heart failure patient, comparing the concentration of IGFBP2 measured in step (i) to a threshold value derived from the concentration of IGFBP2 in samples that have been obtained from patients who are at particular stages of heart failure and/ or to a threshold value derived from the concentration of IGFBP2 in samples that have been obtained from healthy patients 
(i) mjerenja koncentracije IGFBP2 u uzorku dobivenom iz navedenog pacijenta sa srčanom insuficijencijom, (ii) uspoređivanja koncentracije IGFBP2 izmjerene u koraku (i) s graničnom vrijednošću dobivenom iz koncentracije IGFBP2 u uzorcima dobivenim iz pacijenata koji su u pojedinim stadijima srčane insuficijencije iii s graničnom vrijednošću dobivenom iz koncentracije IGFBP2 u uzorcima dobivenim iz zdravih pacijenata.
The process according to claim 39 wherein said step (c) is performed in a continuous stirred tank reactor combined with static mixers in a loop system. 
Postupak prema patentnom zahtjevu 39 gdje se navedeni korak (6) izvodi u reaktoru - spremniku s kontinuiranim miješanjem u kombinaciji sa statičkom miješalicom u sustavu omče.
The method of claim 11, wherein the loading buffer has a conductivity of about 4.0 mS to about 10.0 mS and the elution buffer has a conductivity of about 5.5 mS to about 17.0 mS. 
Postupak prema patentnom zahtjevu 12, naznačen time da pufer za punjenje ima pH od otprilike 4 do otprilike 9, i pufer za eluciju ima pH od otprilike 4 do otprilike 9.
An inserter according to claim 1, characterized in that the first end of the insertion tube (6) comprises two diagonally symmetrical connection slots (20) for receiving a connection part (19) of the intrauterine system (1). 
Aplikator za umetanje prema zahtjevu 1, naznačen time što prvi kraj cjevčice za umetanje (6) obuhvaća dva dijagonalno simetrična ležišta za primanje okvira (1a) intrauterinog sustava (1).
In order to obtain a product in the form of hemipentahydrate monosodium salt, the reaction requires pH of 4.9-5.0. 
Kako bi se dobio produkt u obliku hemi-pentahidratne mononatrijeve soli, reakcija zahtjeva pH od 4.9-5.0.
An example of an atypical antipsychotic agent with a favourable therapeutic application is to be found in the class of polycondensed heterocycles with a pyrrolo[2,1-b]benzothiazepine structure described in the international patent applications WO 00/06579 and WO 02/10175, both filed in the name of the present applicant. 
Primjer atipične antipsihotične tvari s pogodnom terapijskom primjenom naći će se u skupini polikondenziranih heterocikla s pirolo[2,1-b]benzotiazepin strukturom opisanim u međunarodnim patentnim prijavama objavljenim kao WO 00/06579 1 WO 02/10175, oba prijavljena u ime podnositelja ove patentne prijave.
The fluid pressure can press the sealing material in a direction towards a region at the outer surface of the capsule in which the clearance between one of the enclosing members to the outer surface of the capsule, measured without the sealing material, is zero or smaller than the clearance at the initial location of the unpressurized sealing material. 
Tlak fluida može potisnuti materijal za brtvljenje u smjeru prema predjelu na vanjskoj površini čahure, u kojem predjelu je zračnost između jednog od elemenata za obuhvaćanje čahure prema vanjskoj površini čahure, ako se mjeri bez materijala za brtvljenje, nula ili je manja od zračnosti koja je bila na početku na tom mjestu kada materijal za brtvljenje nije bio potisnut.
wherein R1 is a C1-6 alkyl group optionally having substituent(s), a C3-8 cycloalkyl group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); X is —O— or —NR2— wherein R2 is a hydrogen atom or a C1-6 alkyl group; Y is 
R' je C,4 alkil-skupina koja opcijski ima jedan ili više supstituenata, C3.4 cikloalkil-skupina koja opcijski ima jedan ili više supstituenata, ili heterociklička skupina koja opcijski ima jedan ili više supstituenata; X je ili gdje je R* atom vodika ili C, 4 alkil-skupina; Y je a,
The method of claim 1, further comprising presenting an interruption to an operating system, the interruption based on the request for interruption. 
Postupak sukladno Zahtjevu 1, postupak nadalje obuhvaća prezentiranje prekida na operacijski sustav, prekid osjetljiv na zahtjev za prekid.
A receiving channel (12) for receiving the images sent by a sentinel apparatus (3); 
- prijemni kanal (12) za prijem slika poslanih s nadzornim uređajem (3);
o 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; a pharmaceutically acceptable acid or base addition salt thereof, a N -oxide thereof or a stereochemically isomeric form thereof. 
1-(6-bromo-2-metoksi-kinolin-3-il)-4-dimetilamino-2-naftalen-1-il-1-fenil-butan-2-ol; njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov N-oksid ili njegov stereokemijski oblik.
The compound for use according to any one of claims 1 to 3, wherein the administration of the compound reduces the IOP of the affected eye by at least 10%, or by at least 10-20%, or by 20% or more. 
Tvar za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu primjena kapi snižava IOP zahvaćenog oka za najmanje 10%, 1li za najmanje 10-20%, ili za 20% ili više.
In a particular embodiment, the salt is anhydrous hydrogen sulfate salt of Compound 1. 
Sol hidrogen sulfata od Spoja 1 prema zahtjevu 1 ili zahtjevu 2 u amorfnom obliku.
* and wherein said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene, optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N; 
* i pri čemu navedeni alkil, alkenil, alkinil, aril, heterocikl, arilalkilen, arilalkenilen, arilalkinilen, heterociklički-alkilen, heterociklički-alkenilen ili heterociklički-alkinilen, proizvoljno sadrži jedan ili više heteroatoma u skupini alkil(en), alkenil(en) ili alkinil(en), navedeni heteroatomi su odabrani od atoma O, S i N;
The preparations according to the present invention typically contain carrageenan, preferably iota-carrageenan, as an active antiviral ingredient or as the sole active antiviral ingredient at a concentration of from 0.05% to 1% by weight, preferably of from 0.1 to 0.5%, and most preferably of from 0.1 to 0.3% by weight of the ready-for-use preparation. 
PATENTNI ZAHTJEVI Farmaceutski pripravak koji sadrži jota-karagenan kao aktivnu antivirusnu tvar u antivirusno učinkovitoj količini, za upotrebu kao lijek u profilaktičkom ili terapeutskom topikalnom liječenju virusnih infekcija oka uzrokovanih adenovirusom podtipa D ili virusom A influence podtipa H7, uz ograničenje da pripravak u svojoj formulaciji spremnoj za primjenu sadrži ne više od 0.5 % w/v soli metalnog halogenida.
The present invention also relates to the use of a compound of formula I as described above for the manufacture of a medicament for treating a condition or disease mediated by PPARa, PPARY, PPARY-partial agonist or PPARa/Y dual agonist in a mammal. 
Ovaj izum također se odnosi na upotrebu spoja formule I, kao što je opisano gore, u proizvodnji lijeka za liječenje stanja ili bolesti gdje posreduje parcijalni agonist PPARa, PPARy, PPARy ili dvojni agonist PPARa/y kod sisavca.
Thus, the disclosure provides an antibody that binds to an epitope recognised by an antibody having the variable heavy chain sequence recited in SEQ ID NO: 85, and the variable light chain sequence recited in SEQ ID NO: 99. 
(a) varijabilno područje slabog lanca od sekvence SEQ ID NO: 85, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 99;
The organic layer was dried over Na2SO4 and concentrated to give methyl (2-chlorophenyl)acetate 6a (1.08 g, 97.5%) as a yellowish oil. 
Organski sloj osuši se preko Na»SO,, te koncentrira kako bi se dobilo metil-(2-klorfenil)acetat 6a (1,08 8, 97,5 %) u obliku žućkastog ulja.
The homogenate is centrifuged (Beckman Optima™ TL Ultracentrifuge, 48000 g, 30 min at 4° C.). 
Homogenat je centrifugiran (ultracentrifuga Beckman Optima TM TL, 48000 g, 30 min pri 4*C).
The method according to claim 16, wherein the cancer is colorectal cancer. 
Farmaceutski sastav za uporabu prema zahtjevu 12, gdje je navedeni karcinom kolorektalni karcinom.
or R11 and R12 together with carbon atom to which they are attached form a (C3-C8)cycloalkyl or a (C3-C8)-heterocycloalkyl ring; 
Ri3 i Ria, zajedno s N atomom na kojeg su vezani, tvore (C3-Cg) heterocikloalkil;
A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyuria to increase the initial period of undisturbed sleep in a female patient in need thereof, the composition comprising an orodispersible dose of 25 microgram desmopressin wherein the dose is measured as the free base of desmopressin and which is administered to the patient prior to bedtime. 
PATENTNI ZAHTJEVI Pripravak koji sadrži dezmopresin za uporabu u liječenju nokturije ili noćne poliurije za povećanje početnog razdoblja nesmetanog spavanja kod ženskog pacijenta kojem je potreban, naznačen time da pripravak sadrži orodisperzibilnu dozu od 25 mikrograma dezmopresina pri čemu se doza mjeri kao slobodna baza dezmopresina i koja se daje pacijentu prije spavanja.
Process according to claim 1, wherein the sulfuric acid is used in form of a solution in an organic solvent. 
Postupak prema bilo kojem od zahtjeva 1 do 2, naznačen time, da se sumporna kiselina upotrebljava u obliku otopine u organskom otapalu.
Machinery according to claim 5, wherein the machinery is located downstream of an automatic system to form the electro-welded metal nets, at least one of the electro-welded metal nets is flat and has at least one of regular meshes and irregular meshes, and is produced in sequence and on demand, and the machinery is located downstream of an automatic electro-welding assembly. 
Stroj prema jednom zahtjevu od 5 do 9, naznačen time da je postavljen nizvodno od automatskog sustava za formiranje elektro-zavarene metalne mreže, koja je ravna i ima pravilan raspored mreže (1) i/ili nepravilan raspored mreže (1.1), koji proizvodi uzastopno i na zahtjev, te konkretnije nizvodno od automatskog sklopa za elektrozavarivanje (45).
The initial capture step typically involves protein isolation from a crude cell lysate or from cell culture medium and requires a resin with a high capacity and high flow rate. 
Hvatanje je početni korak koji obuhvaća izolaciju proteina iz sirovog staničnog lizata ili iz hranjivog medija, te zahtjeva smolu visokog kapaciteta i velike brzine protoka.
A slide according to claim 1 and it is characterized in that it comprises at least one turnstile (12) along the said sliding lanes (14.1, 14.2). 
Tobogan sukladno zahtjevu 1 naznačen time što obuhvaća barem jedno okretište (12) duž staza za spuštanje
The kit of any one of claims 6 to 11 for use in treatment of a neurological disorder selected from restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, progressive supranuclear palsy, multiple system atrophy, or amyotrophic lateral sclerosis by continuously administering the first composition in conjunction with the second composition. 
Komplet iz bilo kojeg od patentnih zahtjeva 6 do 10, naznačen time, da je namijenjen upoirebi u liječenju neurološkog poremećaja odabranog od: sindroma nemirmih nogu, Parkinsonove bolesti, sekundarnog parkinsonizma, Huntingtonove bolesti ili sindroma sličnog Parkinsonovoj bolesti, kontinuiranim davanjem prvog pripravka zajedno s drugim pripravkom.
represents a hydrogen atom or a bromo atom; 
R* predstavlja vodikov atom ili bromov atom;
A device according to claim 1 or 2, characterized in that the body of permanent-magnetic material is a polymer-bonded composite which comprises a macromolecular polymer and a permanent-magnetic powder, wherein the magnetic powder is selected from the group of magnetic materials comprising cobalt, iron, and their alloys, chromium dioxide, magnetic oxide spinels, magnetic garnets, magnetic ferrites including magnetic hexaferrites, alnico alloys, samarium-cobalt alloys, and rare-earth-iron-boron alloys. 
Uređaj sukladno patentnom zahtjevu 1, naznačen time, da je tijelo od permanentno magnetskog materijala izrađeno od kompozitnog materijala vezanog polimerom koje uključuje makromolekularni polimer i prašak permanentno magnetskog materijala, pri čemu je magnetski prašak odabran iz skupine koju čine magnetski materijali u koje spadaju kobalt, željezo i njihove legure, krom dioksid, magnetski oksid spineli, magnetski granati, magnetski feriti uključujući magnetske heksaferite, alnico legure, legure samarij-kobalta i legure rijetka zemlja-Željezo-bor.
The method according to any of the claims 1 - 7 wherein pressing under pressurized conditions is accomplished using a screw press. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, pri čemu se celulozni materijal podvrgava silama razdvajanja u reaktoru pod tlakom.
The process according to claim 8, wherein said salt of a fatty acid is magnesium stearate. 
Postupak prema patentnom zahtjevu 5, naznačeno time da sol masne kiseline jest magnezijev stearat.
for the treatment of pain. The use according to claim 1, where dose a is within the range of from 10 to 90 wt.-% of dose b. 
Lijek prema patentnom zahtjevu 8, naznačen time da je doza a unutar raspona od 10 do 90 % po težini doze b.
The radioactive metal-labeled anti-p-cadherin antibody of claim 1, wherein a mole ratio of the anti-p-cadherin antibody to the metal-chelating reagent is from 1:0.1 to 1:4.5. The radioactive metal-labeled anti-p-cadherin antibody of claim 4, wherein the mole ratio of the anti-p-cadherin antibody to the metal-chelating reagent is from 1:0.5 to 1:3. 
Anti-P-kadherin antitijelo obilježeno radioaktivnim metalima u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time, da je molni omjer anti-P-kadherin antitijela u odnosu na reagens za keliranje metala od 1: 0,1 do 1: 4,5, poželjno 1: 0,5 do 1: 3.
Crystallization of risedronic acid facilitates the removal of the phosphoric acid, phosphorous acid, and hydrochloric acid produced in the reaction. 
Kristalizacijom risedronske kiseline olakšava se uklanjanje fosfatne kiseline, fosfitne kiseline i kloridne kiseline dobivenih u reakciji.
CG is a connecting group that connects Su to Sp or D; 
CG je spojna skupina koja povezuje Su s Sp ili D;
This difference is indicative of the unknown phase, S in the example shown, relative to the reference phase R in the example. 
(54) Naziv izuma: POSTUPAK | SUSTAV ZA DETEKCIJU FAZNOG VODIČA NEPOZNATOG FAZNOG NAPONA U ODNOSU PREMA REFERENTNOM FAZNOM NAPONU
preparing an aqueous suspension of precipitated calcium carbonate seeds by carbonating a suspension of Ca(OH)2 in the presence of 0.005 to 0.030 moles of Sr, in the form of Sr(OH)2, per mole of Ca(OH)2, and 
(a) dobivanje vodene suspenzije sjemena taložnog kalcijevog karbonata karboniziranjem suspenzije Ca(OH), u prisutnosti od 0.005 do 0.030 mola Sr, u obliku Sr(OH),, po molu Ca(OH),,
A method of making a stabilized aqueous composition of hydrated cloquintocet-mexyl, comprising: mixing anhydrous cloquintocet-mexyl with an aqueous composition comprising water and a wetting surfactant to form an aqueous cloquintocet-mexyl composition; 
Postupak priprave stabiliziranog vodenog pripravka hidratiranog klokintocet-meksila, naznačen time što se sastoji u: miješanju bezvodnog klokintocet-meksila s vodenim pripravkom koji sadrži vodu i močeći surfaktant kako bi se dobilo vodeni pripravak klokintocet-meksila;
Preferably the library is obtained by cloning in the vector of the invention cDNAs from antibody producing cells, more preferably Tumor Infiltrating Lymphocytes (TILs) or Peripheral Blood Lymphocytes (PBLs). 
Biblioteka u skladu s patentnim zahtjevom 5, naznačena time što stanice koje proizvode protutijela su limfociti koji se infiltriraju u tumore (TIL) ili limfociti iz periferne krvi (PBL).
The present invention is a process for preparing crystalline form of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate. 
Spoj, naznačen time, da je (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorid hemihidrat.
a targeter-RNA comprising a nucleotide sequence that is complementary to a target sequence of a target DNA molecule, and 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK; i
The pharmaceutical composition according to claim 10, wherein the at least one additional active agent is chosen from formoterol, salmeterol, budesonide, and mometasone, wherein the at least one additional active agent is in free or pharmaceutically acceptable salt form. 
Farmaceutski pripravak za primjenu prema zahtjevu 8, naznačen time, što je dodatna aktivna tvar odabrana iz formoterola, salmeterola, budezonida i flutikazon propionata, u slobodnom obliku ili u obliku farmaceutski prihvatljive soli.
The pharmaceutical composition of any one of claims 3-5, wherein the pharmaceutical composition has a pH of from about 4 to about 5. 
Farmaceutska kompozicija koja sadrži spoj sa formulom (2): i vodeni pufer, gdje kompozicija ima pH od oko 5 do oko 6.
A molecule that binds to activated hepatocyte growth factor B chain and inhibits specific binding of said activated HGF B chain to c-met. 
Molekula koja se veže na B lanac aktivirnog hepatocitnog faktora rasta i inhibira specifično vezanje spomenutog aktiviranog HGF B lanca na c-met, naznačena time, da spomenuta molekula je:
A male mouse whose germline genome comprises: 
Miš čiji genom sadrži:
Disk and ring are then removed and the assembled container is ejected from the receiving member 20. 
Disk 1 prsten se tada uklone 1 sklopljeni spremnik se izbaci iz elementa za držanje 20.
An apparatus according to claim 15, comprising an ion generator in the base unit. 
Uređaj prema bilo kojem od zahtjeva 8 do 11, naznačen time da sadrži generator iona u osnovnoj jedinici.
Wind system (1) according to claim 8, characterised in that said electric energy collecting windings are controlled by a power electronics. 
Vjetreni sustav (1) prema zahtjevu 4, naznačen time da spomenuti sustavi koji pokreću spojler primaju komande bežičnim putem 1z spomenutog pametnog kontrolnog sustava.
detection of at least one border of the first color, and 
generiranja pomoću kamere, elektroničke slike barem dijela obrasca;
is cyclobutyl, or C(1-4)alkyl, wherein said C(1-4)alkyl is optionally substituted with OCH3 or up to three fluorine atoms; 
Je Ca. »yalkil; A? je ciklobutil, ili Caalkil, pri čemu spomenuti Cq4yalkil je po potrebi supstituiran sa OCH; ili do tri atoma fluora; 10
After drying or hardening the so oriented ink or coating composition, the transferred magnetic image on the imprinted sheet or web remains fixed. 
Nakon sušenja ili otvrdnjavanja usmjerene tinte ili smjese za premazivanje, prenesena magnetska slika ostaje fiksirana na tiskanom listu papira 1li tkanina.
R24A is selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C1-24 alkyl and an optionally substituted —O-aryl; 
A i R24A su neovisno odabrani iz skupine koju čine vodik, po izboru supstituiran C1-24 alkil, po izboru supstituiran aril, po izboru supstituiran -O-C1-24 alkil i po izboru supstituiran -O-aril;
separating the trans-(-)-A9-tetrahydrocannabinol and/or the trans-(+)-A9-tetrahydrocannabinol from the alcoholic-caustic phase; and 
razdvajanje alkoholno-kaustične faze koja sadrži trans-(-)-A9-tetrahidrokanabinol i trans-(+)-A9-tetrahidrokanabinol od prve organske faze;
A nucleotide sequence having at least 85% sequence identity to SEQ ID NO: 1 that codifies for the protein SEQ ID NO: 2. 
Izolirani nukleotidni slijed SEQ 10 NO: 1, naznačen time što kodira protein SEQ 10 NO: 2.
The formulation of claim 1, further comprising at least one of: 
Formulacija prema zahtjevu 1, naznačena time, da sadrži barem jedno od slijedećih:
Preferably, the level of expression of the marker protein or the fragment thereof or the combination of marker proteins or the fragments thereof is detected using a reagent which specifically binds with the marker protein or the fragment thereof or the combination of marker proteins or the fragments thereof. 
Postupak prema bilo kojem zahtjevu 2 do 7, naznačen time, da se razina ekspresije marker-proteina ili njegovog fragmenta ili kombinacije marker-proteina ili njihovih fragmenata otkriva uporabom reagensa koji se specifično veže na marker-protein ili na njegov fragment ili na kombinaciju marker-proteina ili njihovih fragmenata,
The process of claim 5, wherein the overall resid conversion is of at least 95 wt.%. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time, da je ukupna konverzija ostatka najmanje 95 % težinskog udjela.
A piece of fitness equipment comprising: first and second pressure chambers which can be supplied with a fluid and are suitable for wrapping around a body part of a person; 
Fitnes uređaj, koji sadrži: barem jednu tlačnu komoru (20a) koja se koristi s fluidom i koja je pogodna za postavljanje na dio tijela (110a) osobe (100a);
Z is a group represented by -NR3CO-, 
Z je skupina predstavljena sa sljedećim formulama:
The compound of Paragraph 1, wherein R5 is represented by the following structural formula: wherein: 
Spoj prema zahtjevu 1, pri čemu je Rs prikazan slijedećom strukturnom formulom:
first capsule detaching means for actively detaching the capsule (24) from the first jaw member, and 
- - prvo sredstvo za aktivno odvajanje čahure (24) iz prvog elementa čahure, i